Haemonetics Corporation (HAE)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $5.53B
Last updated: Nov 17, 2026 at 4:28 PM ET
Haemonetics Corporation (HAE) Statistics
Haemonetics (HAE) has a market cap of $5.53B and an enterprise value of $6.39B. Its share count is down 4.39% from a year earlier.
Total Valuation
Enterprise value is 15.62% above the market cap, as debt exceeds cash.
| Market Cap | $5.53B |
|---|---|
| Enterprise Value | $6.39B |
| Latest price (Nov 17, 2026) | $120.97 |
Key Dates
The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | March |
Valuation Ratios
Sales and book value multiples are 4.0x and 6.1x. Its year-end P/E ranged from 16.3x to 46.0x from 2016 to 2025.
| P/E Ratio | 23.8x |
|---|---|
| Forward P/E | 22.5x |
| P/S Ratio | 4.0x |
| Forward P/S | 3.8x |
| P/B Ratio | 6.1x |
| P/FCF Ratio | 18.5x |
| P/OCF Ratio | 16.0x |
| PEG Ratio | 2.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 25.2x EBITDA and 21.3x free cash flow.
| EV / Earnings | 61.5x |
|---|---|
| EV / Sales | 4.6x |
| EV / EBITDA | 25.2x |
| EV / EBIT | 45.0x |
| EV / FCF | 21.3x |
Price Statistics
The stock is up 64.61% over 52 weeks and trades 6.08% above its 50-day average.
| Beta (1Y) | 0.27 |
|---|---|
| 52-Week Change | +64.61% |
| 1-Month Change | +1.89% |
| 3-Month Change | +11.59% |
| 6-Month Change | +112.79% |
| 5-Year Change | +74.14% |
| 10-Year Change | +258.13% |
| Total Return (1Y) | +64.61% |
| Total Return (3Y CAGR) | +13.28% |
| Total Return (5Y CAGR) | +16.69% |
| Return vs SPY (1Y) | +51.03% |
| Max Drawdown (1Y) | -40.06% |
| Max Drawdown (3Y) | -51.04% |
| Sharpe Ratio (1Y) | 1.22 |
| Correlation with SPY (1Y) | 0.09 |
| 50-Day Average | $114.04 |
| 200-Day Average | $81.81 |
| 52-Week Range | $51.00 to $132.00 |
| RSI (14 Days) | 54.5 |
| Average Volume (20 Days) | 695.36K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.84x current liabilities, and total debt is 1.25x shareholder equity.
| Current Ratio | 2.84x |
|---|---|
| Quick Ratio | 1.83x |
| Debt / Equity | 1.25x |
| Debt / EBITDA | 4.44x |
| Debt / FCF | 3.77x |
Returns and Efficiency
Return on invested capital is 5.14% over the last 12 months, against a 5-year average of 5.96%.
| Return on Equity (ROE) | 11.56% |
|---|---|
| Return on Assets (ROA) | 4.31% |
| Return on Invested Capital (ROIC) | 5.14% |
| Return on Capital Employed (ROCE) | 6.73% |
| ROE (5Y Average) | 12.96% |
| ROA (5Y Average) | 4.91% |
| ROIC (5Y Average) | 5.96% |
| Asset Turnover | 0.57x |
| Inventory Turnover | 1.82x |
| Receivables Turnover | 6.27x |
| Cash Conversion Cycle | 216 days |
Taxes
Income tax took 26.83% of pretax income over the last 12 months.
| Income Tax (TTM) | $38.10M |
|---|---|
| Effective Tax Rate | 26.83% |
Scores
HAE has an Altman Z-Score of 3.44, in the safe zone above 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.44 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $1.38B over the last 12 months is up 4.11% from the 12 months before.
| Revenue | $1.38B |
|---|---|
| Revenue Growth (YoY) | +4.11% |
| Gross Profit | $824.31M |
| Operating Income | $176.95M |
| Pretax Income | $142.01M |
| Net Income | $103.91M |
| EBITDA | $252.91M |
| EBIT | $142.01M |
| Reported EPS (TTM) | $5.09 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 37.28% of the $2.41B in total assets.
| Cash and Equivalents | $260.71M |
|---|---|
| Total Debt | $1.12B |
| Net Debt | $863.05M |
| Net Debt Per Share | $18.97 |
| Working Capital | $554.69M |
| Shareholder Equity | $898.50M |
| Book Value Per Share | $19.75 |
| Tangible Book Value | -$184.97M |
| Total Assets | $2.41B |
| Total Liabilities | $1.51B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $46.69M of capital spending, operating cash flow left $298.24M of free cash flow.
| Operating Cash Flow | $344.93M |
|---|---|
| Capital Expenditures | $46.69M |
| Free Cash Flow | $298.24M |
| FCF Per Share | $6.56 |
| Depreciation and Amortization | $110.90M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 12.80%, against a 5-year average of 12.43%.
| Gross Margin | 59.63% |
|---|---|
| Operating Margin | 12.80% |
| Pretax Margin | 10.27% |
| Net Margin | 7.52% |
| EBITDA Margin | 18.29% |
| EBIT Margin | 10.27% |
| FCF Margin | 21.57% |
| Gross Margin (5Y Average) | 54.09% |
| Operating Margin (5Y Average) | 12.43% |
| Net Margin (5Y Average) | 8.57% |
Growth
Revenue grew 4.51% a year over 3 years, and EPS 17.93% a year.
| Revenue Growth (3Y CAGR) | +4.51% |
|---|---|
| Revenue Growth (5Y CAGR) | +8.91% |
| EPS Growth (3Y CAGR) | +17.93% |
| EPS Growth (5Y CAGR) | +16.16% |
| FCF Growth (3Y CAGR) | +47.15% |
| FCF Growth (5Y CAGR) | +29.41% |
| Operating Income Growth (3Y CAGR) | +0.15% |
| Book Value Per Share Growth (2Y CAGR) | -3.95% |
Dividends and Yields
HAE does not pay a dividend. Its free cash flow yield is 5.42%.
| Earnings Yield | 4.20% |
|---|---|
| FCF Yield | 5.42% |
| Buyback Yield | 1.82% |
| Shareholder Yield | 1.82% |
Stock Splits
The last split was a 2-for-1 forward split on Dec 3, 2012.
| Last Split Date | Dec 3, 2012 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 9 similar companies, HAE has the 6th highest P/E.
P/E RatioPeer median 31.5x
P/S RatioPeer median 3.5x
ROICPeer median 6.99%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +12.52%
| P/E Ratio | 23.8x vs 31.5x median |
|---|---|
| P/S Ratio | 4.0x vs 3.5x median |
| ROIC | 5.14% vs 6.99% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4.11% vs +12.52% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.07% and EPS growth at 11.70% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +9.07% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +11.70% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About HAE
What is HAE's market cap?
Haemonetics has a market cap of $5.53B. Its enterprise value, which adds debt and subtracts cash, is $6.39B.
What is HAE's P/E ratio?
Haemonetics has a trailing P/E ratio of 23.8x and a forward P/E of 22.5x.
How many shares of HAE are outstanding?
Haemonetics has 45.50M shares outstanding. The count is down 4.39% from a year earlier.
Does HAE pay a dividend?
No. Haemonetics does not pay a dividend.
How much debt does HAE have?
Haemonetics has $1.12B of total debt and $260.71M of cash and equivalents, a net debt position of $863.05M.
HAE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts